Become a MemberHomeJoin Mailing ListContact Us

Scientifc Programme

 

  Virtual Meeting   Posters online
       
  Abstracts online   Onsite Program

 

Building on the success of previous conferences, the theme of the 2013 meeting

 

'Next-Generation Lung Cancer Care'

 

will reflect the need for collaboration and cooperation in producing the best possible outcomes in the treatment of lung cancer. It is also a reflection of the nature of the International Association for the Study of Lung Cancer which welcomes and encourages the participation of individuals from a wide range of professional backgrounds in its Conferences.

 

The 15th WCLC will provide the ideal forum for you to learn about and contribute to innovations in science and advances in the treatment of lung cancer.

 

The Core Program Committee is pleased to present an outstanding and exciting Scientific Program with more than 250 world renowned speakers and chairs participating in more than 160 scientific sessions. Please see further details below.

 

Last program update: October 14, 2013

 

 

Scientific Program

 

 

Sessions at a Glance

 

  Sunday, October 27 Monday, October 28 Tuesday, October 29 Wednesday, October 30
  Session Overview Sunday, October 27 SEssion Overview MOnday Session Overview Tuesday October 29 Session Overview Wedensday October 30

Click on image to enlarge. Sessions subject to change...

 

Click here to download Sessions at a Glance (pdf, last updated October 25, 2013) >>

 

Program at a Glance

Click on image to enlarge. Sessions subject to change...

 

Click here to download Program at a Glance (pdf, last updated October 1, 2013) >>

 

 

 

Program in chronological order

 

 

 

Saturday, October 26

iMig-NCARD Satellite Meeting prior to the 15th World Conference on Lung Cancer

Location: Novotel on Sydney Darling Harbour

Time: 08:30 - 17:30

Click here for more information (pdf) >>

iMig-NCARD Program (pdf) >>

 

 

  Sunday, October 27
  07:30 - 12:00

C: INAUGURAL COCHRANE WORKSHOP
incl. Coffee Break

Location: Bayside 204 A+B, Level 2

Chairs: Rami Ramon-Porta, Spain & Fergus Macbeth, UK

 

  • 07:30 - C.01: Introduction to Writing a Cochrane Review - Fergus Macbeth, UK
  • 07:50 - C.02: Writing a Protocol - Noelle O'Rourke, UK
  • 08:10 - C.03: Defining a Review Question - Kwun Fong, Australia
  • 08:30 - C.04: Searching for Studies and Selecting Studies - Virginie Westeel, France
  • 09:10 - C.05: Collecting Data - Nick Pavlakis, Australia

     

    09:30 - Coffee Break

     

  • 10:00 - C.06: Analysing Dichotomous Data - Chee Lee, Australia
  • 10:15 - C.07: Analysing Continuous Data - Chee Lee, Australia
  • 10:30 - C.08: Analysing Non-Standard Data and Designs - Chee Lee, Australia
  • 10:45 - C.09: Assessing Bias in Included Studies - Lisa Askie, Australia
  • 11:00 - C.10: Introduction to Meta-Analysis - Lisa Askie, Australia
  • 11:15 - C.11: Assessing Small Study Effects and Reporting Bias - Lisa Askie, Australia
  • 11:30 - C.12: Introduction to RevMan - Ian Yang, Australia
  • 11:50 - C.13: Feedback and Closing Remarks - Rami Ramon-Porta, Spain & Fergus Macbeth, UK
 
       
  07:30 - 12:00

CALC: CHINESE ALLIANCE AGAINST LUNG CANCER SESSION

incl. Morning Tea and Chinese Poster Review

Location: Parkside Auditorium, Level 1

Simultaneous Translation English >< Mandarin
provided for this session

 

Part 1 Chairs: Chunxue Bai, China & Yi-Long Wu, China

  • 07:30 - CALC.01:Welcome - Chunxue Bai, China & Yi-Long Wu, China
  • 07:40 - CALC.02: Keynote: Epidemiology and Burden of Smoking Related Diseases in China - Chunxue Bai, China
  • 08:30 - CALC.03: Pathogenesis and Pathology of Never Smoking Lung Cancer - Adi Gazdar, USA
  • 08:50 - CALC.04: SBRT for Lung Cancer - Min Fan, China
  • 09:10 - CALC.05: COPD and Lung Cancer - Ian Yang, Australia

    09:25 - Morning Tea and Chinese Poster Review

Part 2 Chairs: Chunxue Bai, China & David Lam, Hong Kong

  • 09:55 - CALC.06: Diagnosis of Lung Nodules by CT-Guided Lung Biopsy - Yong Song, China
  • 10:05 - CALC.07: Molecular Signatures for the Accurate Classification of NSCLC and Neuroendocrine Tumors and Cell Lines - Adi Gazdar, USA
  • 10:25 - CALC.08: Targeted Therapies for Adenocarcinoma, Now and Future - Caicun Zhou, China
  • 10:45 - CALC.09: Targeted Therapies for SCC, Now and Future - Tony Mok, Hong Kong
  • 11:05 - CALC.10: Second Line Treatment of NSCLC: Needed to Detect Driven Gene Mutation Status - Baohui Han, China
  • 11:15 - CALC.11: MicroRNA Biomarkers in Lung Cancer - Shaohua Lu, China
  • 11:25 - CALC.12: IPF Caused by EGFR-TKIs in Asia - Qunying Hong, China
  • 11:35 - CALC.13: Novel Lung Cancer Plasma Immunoinflammatory Complexes - Li Zhang, China
  • 11:45 - CALC.14: Summary and Close - Chunxue Bai, China & David Lam, Hong Kong
 
       
       
  08:00 - 11:30

Y: YOUNG INVESTIGATOR & FIRST TIME ATTENDEE SESSION

incl. Breakfast and Coffee Break

Location: Parkside Ballroom A+B, Level 1

Chairs: Martin Edelman, USA & Gilberto Lopes, Singapore

     

    08:00 - Breakfast

  • 08:30 - Y.1: Planning an Academic Career in Lung Cancer - Natasha Leighl, USA
  • 08:50 - Y.2: How to Present Data at a Conference - Michael Boyer, Australia
  • 09:10 - Y.3: How to Write a Grant Application for the IASLC - Karen Kelly, USA
  • 09:30 - Y.4: How to Get your Papers Published - James Jett, USA
  • 09:50 - Y.5: Using the Published Literature Effectively - Martin Stockler, Australia

     

    10:20 - Coffee Break

     

  • 10:40 - Y.6: Making the Most of the WCLC: A Guide for First Time Attendees - Primo Lara, USA
  • 11:00 - Y.7: Q&A and Networking Opportunity with Longstanding IASLC Members
 
       
  10:00 - 12:00

ADDICTION INCORPORATED (MOVIE SCREENING)

Location: Bayside Auditorium B, Level 1

Chairs: Carolyn Dresler, USA & Mike Daube, Australia

 

Addiction Incorporated Documentary Screening: The true story of the tobacco companies' commitment to addicting the human brain, and how the world came to know about it. Featuring a post-screening panel discussion with Dr. Carolyn Dresler and Dr. Mike Daube.

 

Addiction Incorporated

 
       
  10:00 - 15:00

ABBOTT HANDS-ON TRAINING SESSION

 

Molecular Diagnosis of Gene Fusions by FISH for Targeted Therapy

Lunch Boxes will be provided

Location: Parkside 110 A+B, Level 1
Chair: Marileila Varella Garcia, USA

 

This interactive educational activity is directed to medical professionals aiming to discuss scoring of ALK FISH in lung cancer specimens. The session includes individual case reviews of a variety of patients.

 

For more information >>

 
       
  12:00 - 13:30

INDUSTRY SUPPORTED SYMPOSIUM supported by Boehringer Ingelheim: Questions in the Treatment of NSCLC: Targeting Angiogenesis

Location: Bayside Auditorium A, Level 1

 
       
  12:30 - 17:00

ITONF: INTERNATIONAL THORACIC ONCOLOGY NURSING FORUM - WORKSHOP/MEETING

Location: Bayside Gallery A, Level 1

Chair: Beth Ivimey, Australia

 

  • 12:30 - ITONF.01: Opening of Workshop (ITONF Update and Workshop Intro) - Beth Ivimey, Australia
  • 12:40 - ITONF.02: Preparing Nurses for the Next Generation of MDT Lung Cancer Care - Mei Krishnasamy, Australia
  • 13:35 - ITONF.03: Out of the Shadows into the Clinic - Stigma Impacting on Late Presentations - Janine Cataldo, USA
  • 14:05 - ITONF.04: Survivorship - How Do We Define in Lung Cancer - Caitlin Broderick, Australia

     

    14:30 - Coffee Break

     

  • 15:00 - ITONF.05: Positive Impact of Specialist Lung Cancer Nurses on Better Patient Outcomes - Angela Tod, UK
  • 15:40 - ITONF.06: Non-Pharmacological Management of Breathlessness and Cough - Alex Molassiosis, Hong Kong
  • 16:20 - ITONF.07: Workshop Close / Questions - Beth Ivimey, Australia
  • 16:30 - ITONF Members Meeting / Discussion

For further information, please click here >>

 

Note: Attendance of this workshop is free for all registered WCLC 2013 delegates; however, for seating purposes we kindly ask you to send an email to Glenda Colburn if you plan to attend.

Nurses/Supportive Care
       
  12:30 - 16:00

SUPERDIMENSION HANDS ON TRAINING SESSION

 

Introduction to Electromagnetic Navigation Bronchoscopy

Location: Bayside Gallery B, Level 1

Chair: Douglas Minnich, USA

 

The primary objective for this activity is to introduce physicians to the Superdimension Electromagnetic Navigation Bronchoscopy System. Key program components will include didactic presentations by key opinion leaders as well as hands-on planning and procedure lab exercises.

 

  • 12:30 - Clinical Background
  • 13:00 - Review Electromagnetic Navigation Bronchsoscopy
  • 13:30 - ENB Lab Sessions
    - Planning Station
    - Navigation Station
    - Sampling Station
    - Markers for SBRT Station
    - Markers for Localization Station
  • 15:30 - Business & Clinical Case Studies

For further information >>

 

IMPORTANT NOTE: Registration required for this session

To register for the program,

 

 
       
  13:00 - 15:00

A Focus on Lung Cancer - An Interactive Consumer Forum

Location: Bayside 204 A+B, Level 1

 

  • 13:00 - Welcome - Glenda Colburn, Australia
  • 13:05 - Standardisierung Lung Cancer Around the World - David Carbone, USA
  • 13:15 - Tackling Lung Cancer in Australia - Improving Patient Outcomes - Helen Zorbas, Australia
  • 13:25 - Lung Cancer Screening - Where Are We At? - Henry Marshall, Australia
  • Advances in Diagnosing Lung Cancer
  • 13:45 - Advances in Lung Cancer Treatment - David Carbone, USA
  • 13:55 - Patients Powering Progress - Bonnie J. Addario, USA

     

    14:05 - Coffee Break

     

  • 14:15 - Interactive Q&A Session with Panel
  • 15:15 - Forum Summary followed by light refreshments
 
       
  14:00 - 15:30

INDUSTRY SUPPORTED SYMPOSIUM supported by AstraZeneca: Future Concepts in EGFR Mutation-Positive Advanced NSCLC

Location: Parkside Auditorium, Level 1

 
       
  16:00 - 17:30

INDUSTRY SUPPORTED SYMPOSIUM supported by Pfizer: Preparing for Tomorrow: Molecular Diagnostics and the Changing NSCLC Landscape

Location: Parkside Ballroom A+B, Level 1

 
       
  17:30 - 18:30

G01: PROGRESS IN LUNG CANCER: CELEBRATING 40 YEARS OF IASLC AND RESEARCH PROGESS

Location: Parkside Auditorium, Level 1

Chairs: Tony Mok, Hong Kong & Peter Goldstraw, UK

 

In this session experts will highlight developments in different areas of lung cancer and thoracic oncology over the last 40 years.

  • 17:30 - G01.1: Surgery and Staging - Hisao Asamura, Japan
  • 17:45 - G01.2: Early Detection, Etiology, Epidemiology, Pulmonology and Radiology - Pieter E. Postmus, Netherlands
  • 18:00 - G01.3: Biology and Pathology - Fred Hirsch, USA
  • 18:15 - G01.4: Non-Surgical Therapy - Paul A. Bunn Jr., USA
 
       
  18:45 - 20:15

PL01: OPENING PLENARY SESSION

Location: Plenary Hall, Ground Level

Chairs: Michael Boyer, Australia & Kwun Fong, Australia


  • Welcome to Country
  • Welcome Speeches and Award Ceremonies (IASLC Distinguished Awards)
  • PL01.01: 40 Years IASLC - Fred Hirsch, USA
  • Click here to download Dr. Hirsch's presentation >>

     

  • PL01.02: Keynote Address: 'You Can Take on the Tobacco Industry and Win' - The Honourable Nicola Roxon, Australia

    Click here to download Ms. Roxon's presentation (pdf) >>

     

  • Nicola Roxon is an Australian politician, who was a member of the Australian House of Representatives representing the seat of Gellibrand in Victoria for the Australian Labor Party from the 1998 federal election until her retirement in August 2013. Between 2011 and 2013, Roxon was the Attorney-General of Australia and between 2007 - 2011 the Minister for Health and Ageing of Australia. Ms Roxon received national and international awards for her leadership in introducing plain packaging of tobacco products, including the WHO Director-General’s Special Recognition certificate in 2011.

 
       
  20:15 - 21:30

WELCOME RECEPTION - OFFICIAL OPENING EXHIBIT HALL

Location: Exhibit Hall, Ground Level

 
       
       
       
     
  Monday, October 28
  07:00 - 08:00

CONCURRENT INDUSTRY SUPPORTED SYMPOSIA

 

  • Symposium supported by Celgene: Tackling the Challenges of Squamous Cell NSCLC Patients
    Location: Parkside Ballroom A, Level 1
  • Symposium supported by Myriad: Validation of a 46-Gene Expression Signature in Early-Stage Non-Small-Cell Lung Cancer
    Location: Parkside 110 A+B, Level 1
  • Symposium supported by Boehringer Ingelheim: Let's Discuss: Optimising Treatment of Advanced NSCLC
    Location: Parkside Auditorium, Level 1
  • Symposium supported by Peregrine Pharmaceuticals: Immune Checkpoints in the Tumor Environment: Novel Targets and the Clinical Promise of Combined Immunotherapies
    Location: Parkside Ballroom B, Level 1
 
       
  07:00 - 08:00

IASLC BUSINESS MEETING

Location: Bayside Auditorium A, Level 1

Breakfast provided (Foyer Bayside, Level 1)

 

  • Update on IASLC Activities
  • Update on IASLC Projects
  • Update on the future of WCLC
  • Award Presentations for Developing Nation, Young Investigator, Advocacy Travel Awards
  • Introduction of new IASLC Board Members
 
       
  07:00 - 08:00

Tobacco Control: From Plain Packaging to Smoke-Free Generations

Discussion

Location: Bayside 201 - 203, Level 2

Chairs: The Honourable Nicola Roxon, Australia & Carolyn Dresler, USA & Mike Daube, Australia

 

  • Where to next regrading tobacco control?
  • What needs to be done to make this happen?
  • How other countries could move forward on plain packaging?
  • What are your thoughts on TPPA?
  • What is Australia doing with regard to TPPA negotiations?

A panel discussion with

  • The Honourable Nicola Roxon, Australia
  • Mike Daube, Professor of Health Policy at Curtin University
  • Carolyn Dresler, Member of the IASLC Board of Directors
  • Members of the IASLC Tobacco Control Committee
  • Others
Prevention & Epidemiology
       
  07:00 - 08:00

CONCURRENT MEET THE EXPERT SESSIONS

(ticketed sessions, incl. continental breakfast)

 

  07:00 - 08:00

MTE01: NLST - Additional Lessons and Future Directions

Meet the Expert Session (ticketed)

Location: Bayside Gallery B, Level 1

Speaker: Christine Berg, USA

 

The aim of this session is to provide an overview of other lessons learnt from NLST apart from lung cancer results; smoking cessation, risk prediction, non-cancer findings.


Imaging/Screening
  07:00 - 08:00

MTE02: Mouse Models of Oncogenic Drivers in NSCLC

Meet the Expert Session (ticketed)

Location: Bayside Gallery A, Level 1

Speaker: Kwok-Kin Wong, USA

 

The Key Learning Objectives of this MTE session are:

  1. To describe the use of transgenic mouse models in NSCLC to model therapies and evaluate resistance.
  2. To describe the status of mouse models for small cell lung cancer.

Biology
  07:00 - 08:00

MTE03: Neuroendocrine Tumours of the Lung

Meet the Expert Session (ticketed)

Location: Bayside 106, Level 1

Speaker: Joel Guigay, France

 

The aim of this session is to provide an overview of the pathology and treatment of neuroendocrine tumours of the lung.


Medical Oncology
  07:00 - 08:00

MTE04: Submit Your Challenging Cases for Discussion and Debate!

Meet the Expert Session (ticketed)

Location: Bayside 105, Level 1

Chair: Edwina Duhig, Australia

Speakers: Andrew Nicholson, UK & Kirk Jones, USA

 

This session is aimed at exploring difficulties in arriving at a pathological diagnosis of lung cancer and we invite all attendees to provide cases for discussion that you found difficult. The problems you face may include something that you haven’t seen before or that you have difficulty applying criteria. It may be that you would like to know when something should be called rather than another diagnosis. No question is too small or big.

 

This session is not just for pathologists because it will show the thought processes that go into diagnosis on biopsy or resection specimens. We will show cases and allow Dr. Andrew Nicholson and Dr. Kirk Jones to work through the problems.

 

If you wish to contribute questions, and in particular cases, please submit the followingform.


Pathology
  07:00 - 08:00

MTE05: Navigation Bronchoscopy

Meet the Expert Session (ticketed)

Location: Bayside 104, Level 1

Speaker: Takashi Ishida, Japan

 

Navigation bronchoscopy offers an improved diagnostic yield using 3D image and electromagnetic guidance to guide the bronchoscope or a working sheath towards a pulmonary nodule or other localized abnormality. This is not a hands-on session so the emphasis will be on background and implementation for those clinicians who are considering or have recently implemented ENB.


Pulmonology
  07:00 - 08:00

MTE06: Molecular Pathology Approach for Early Clinical Stage Mesothelioma: Cytological Diagnosis, and Reactive Mesothelial Hyperplasia

Meet the Expert Session (ticketed)

Location: Bayside 103, Level 1

Speaker: Sonja Klebe, Australia

 

This session provides a balanced overview of the challenges faced by the pathologist in the diagnosis of early stage mesothelioma, including cytological diagnosis.


Mesothelioma
  07:00 - 08:00

MTE07: Chest Wall Recon: Materials, Artificial Ribs

Meet the Expert Session (ticketed)

Location: Bayside 102, Level 1

Speaker: Michael Weyant, USA

 

This MTE session will describe techniques for reconstruction of chest wall defects, including the different materials available, their advantages and disadvantages.


Surgery
  07:00 - 08:00

MTE08: Smoking Cessation

Meet the Expert Session (ticketed)

Location: Bayside 101, Level 1

Speaker: Nancy Rigotti, USA

 

This session will bring the most recent data on the positive effects of smoking cessation, the risk factors for Lung Cancer in non-smokers, the effect of Lung Cancer screening by low-dose CT and the place of biomarkers in Lung Cancer screening.


Epidemiology
       
       
     
  08:15 - 09:45

PL02: Will Personalised Therapies Ever "Cure" Metastatic NSCLC?

PLENARY SESSION

Location: Plenary Hall, Ground Level

Chairs: David Gandara, USA & Desmond Carney, Ireland

 

The aim of this plenary session is to explore how targets are identified for personalised therapies, and how properties of tumours, such as epigenomics and tumour heterogeneity may present an obstacle to the success of personalised therapies. Finally, there will be exploration of what is meant by “Cure” in the setting of personalised, targeted treatments.

 

  • 08:15 - Chair Intro
  • 08:20 - PL02.1: Identifying Druggable Targets Through Whole Genome Sequencing: TCGA - Matthew Meyerson, USA
  • 08:40 - PL02.2: Dark Matter: Defining Oncogenic Drivers in the Epigenome - Charles Rudin, USA
  • 09:00 - PL02.3: Tumour Heterogeneity as an Obstacle to Cure - Charles Swanton, UK
  • 09:20 - PL02.4: What Is Cure and How Can We Achieve This With Targeted Therapies? - Tony Mok, Hong Kong

 

Biology/Medical Oncology
     
  09:45 - 10:30

NETWORKING BREAK AND POSTER SESSION

Location: Exhibit Hall, Halls 4 + 5, Exhibition Centre, Ground Level

 

  09:55 - 10:20

EXHIBIT SHOWCASE SESSION: Boehringer Ingelheim: Spotlight Review of the Boehringer Ingelheim Oncology Portfolio

Location: Exhibit Showcase Theater, Exhibit Hall, Ground Level

 
     
  10:30 - 12:00

CONCURRENT ORAL AND MINI ORAL ABSTRACT SESSIONS

 

Click here for further abstract information.

 

Oral Abstract Sessions:

  • O01: Prognostic and Predictive Biomarkers I
    Location: Parkside Auditorium, Level 1
  • O02: NSCLC - Combined Modality Therapy I
    Location: Parkside Ballroom B, Level 1
  • O03: NSCLC - Targeted Therapies I
    Location: Bayside Auditorium B, Level 1
  • O04: Molecular Pathology I
    Location: Parkside Ballroom A, Level 1
  • O05: Cancer Control
    Location: Bayside Auditorium A, Level 1
  • O06: Cancer Control & Epidemiology I
    Location: Bayside 104, Level 1
  • O07: Supportive and Surgical Care
    Location: Bayside Gallery A, Level 1

Mini Oral Abstract Sessions:

  • MO01: Lung Cancer Biology - Techniques and Platforms
    Location: Bayside 204 A+B, Level 2
  • MO02: General Thoracic and Minimally Invasive Surgery
    Location: Parkside 110 A+B, Level 1
  • MO03: Thymic Malignancies
    Location: Bayside Gallery B, Level 1
     
  12:15 - 13:45

INDUSTRY SUPPORTED SYMPOSIUM supported by Lilly Oncology: The Continuous Evolution of Treatment in Advanced NSCLC

Location: Plenary Hall, Ground Level

       
  12:15 - 12:45

EXHIBIT SHOWCASE SESSION: Caris Life Science: Caris Molecular Intelligence: The Lung Experience

Location: Exhibit Showcase Theater, Exhibit Hall, Ground Level

 
       
  12:15 - 13:45

PRESS CONFERENCE: TOP ABSTRACTS

Location: Bayside 101, Level 1

 
     
  14:00 - 15:30

CONCURRENT MINI SYMPOSIA AND EDUCATIONAL SESSIONS

 

  14:00 - 15:30

MS03: The Cutting Edge of Molecularly Targeted Therapy

Mini Symposium

Location: Plenary Hall, Ground Level

Chairs: Nagahiro Saijo, Japan & Heather Wakelee, USA

 

The aim of this session is to provide a forum to discuss the latest information about the identification of novel targets in both small cell and non-small cell lung cancer together with new therapies that are in development for these and other targets. At the end of the session, attendees should be aware of the range and types of new targets that are being identified. They should also understand the drugs that are in development, and what stage these agents are in the process of evaluation.

 

  • 14:00 - Chair Intro
  • 14:05 - MS03.1: Novel Targets in Small Cell Cancer - Roman Thomas, Germany
  • 14:30 - MS03.2: Novel Targets in Squamous Cancer - Peter Hammerman, USA
  • 14:55 - MS03.3: Novel Targets in Adenocarcinoma - Matthew Meyerson, USA

Medical Oncology
  14:00 - 15:30

E03: Chemotherapy for NSCLC

Educational Session

Location: Bayside Auditorium A, Level 1

Chairs: Robert Pirker, Austria & James Bishop, Australia

 

This is an education session covering various aspects of non-small cell lung cancer.

 

  • 14:00 - Chair Intro
  • 14:05 - E03.1: Maximising the Benefit of Chemotherapy for Advanced NSCLC - Giuseppe Giaccone, USA
  • 14:25 - E03.2: Selecting Patients for Maintenance Therapy - Luis Paz-Ares, Spain
  • 14:45 - E03.3: Optimal Adjuvant Chemotherapy: Selection of Patients and Agents - Karen Kelly, USA
  • 15:05 - E03.4: Lung Cancer in Women - Silvia Novello, Italy

Medical Oncology
  14:00 - 15:30

MS02: Stem Cells and Epigenetics in Lung Cancer

Mini Symposium

Location: Bayside 103, Level 1

Chairs: Gabriella Sozzi, Italy & John Minna, USA

 

In this session an overview of the cell of origin of small cell and NSCLC, responsible signaling pathways, as well as potential strategies to target cancer stem cells will be provided. The role of epigenetic alterations, including DNA methylation and microRNA in lung cancer pathogenesis and potential for therapeutic manipulation of these changes will be discussed.

 

  • 14:00 - Chair Intro
  • 14:05 - MS02.1: Stem Cells and The Cell of Origin of Lung Cancer - Kate Sutherland, Australia
  • 14:25 - MS02.2: Targeting Hedgehog Signaling in Small Cell Lung Cancer - Neil Watkins, Australia
  • 14:45 - MS02.3: Micro-RNA in Lung Cancer - Gabriella Sozzi, Italy
  • 15:05 - MS02.4: Targeting Epigenetic Changes in Lung Cancer - Charles Rudin, USA

Biology
  14:00 - 15:30

E06: Issues in Current Multidisciplinary Practice

Educational Session

Location: Bayside 204 A+B, Level 2

Chairs: Laurie Gaspar, USA & Michael Millward, Australia

 

This educational session will provide a summary of current state of the art practice in combined modality therapy in NSCLC, emphasizing the multidisciplinary nature of this treatment.

 

  • 14:00 - Chair Intro
  • 14:05 - E06.1: Optimal Chemotherapy in Combined Modality Therapy for NSCLC - Everett Vokes, USA
  • 14:25 - E06.2: Staging and Early Response Assessment in Combined Modality Therapy for NSCLC - David Ball, Australia
  • 14:45 - E06.3: Management of NSCLC Involving the Chest Wall - Dominique Grunenwald, France
  • 15:05 - E06.4: Treating the 'Borderline' Patient (Moderate PS, Large Tumour etc) - Laurie Gaspar, USA

Combined Modality
  14:00 - 15:30

MS07: Epidemiology and Prevention

Mini Symposium

Location: Bayside Auditorium B, Level 1

Chairs: Keunchil Park, Korea & Nico van Zandwijk, Australia

 

This session summarizes the evidence available on successful tobacco control measures, the comorbidities observed in Lung Cancer patients, susceptibility factors for Lung Cancer and differences in Lung Cancer incidence in various populations.  

 

  • 14:00 - Chair Intro
  • 14:05 - MS07.1: Successful Tobacco Control Approaches in the 21st Century - Matthew Steliga
  • 14:25 - MS07.2: Comorbidity & Competing Causes of Death in Lung Cancer Patients - Maryska Janssen-Heijnen, Netherlands
  • 14:45 - MS07.3: Genetic Susceptibility - Chris Amos, USA
  • 15:05 - MS07.4: Risk Prediction Models - Margaret Spitz, USA

Epidemiology
  14:00 - 15:30

E01: LDCT Screening

Educational Session

Location: Parkside Auditorium, Level 1

Chairs: Ugo Pastorino, Italy & Hans Daniels, Netherlands

 

This educational session aims to develop and enhance knowledge resulting from modern LDCT screening for lung cancer including understanding how risk stratification may improve the efficiency of CT screening programs, the role of volumetrics for assessing nodules, the unique characteristics of screen detected nodules and cancers, as well as up-to-date IASLC recommendations.

 

  • 14:00 - Chair Intro
  • 14:05 - E01.1: Risk Stratification for Lung Cancer Screening Studies - Martin Tammemagi, Canada
  • 14:25 - E01.2: Volumetrics for Nodule Assessment - Matthijs Oudkerk, Netherlands
  • 14:45 - E01.3: Molecular Pathology/Profiling of CT Detected Nodules - Wan Lam, Canada
  • 15:05 - E01.4: Implementing Screening: Recommendations from the IASLC - John Field, UK

Imaging/Screening
  14:00 - 15:30

MS04: Mesothelioma Genetics and Novel Targets

Mini Symposium

Location: Bayside 104, Level 1

Chair: Robert Doebele, USA & Anna Nowak, Australia

 

This session provides an update on the tumour genetics, rather than the germline genetics, of mesothelioma, with a focus on known mutations, discovery, and what impact the somatic genetics of mesothelioma may have on therapy.

 

  • 14:00 - Chair Intro
  • 14:05 - MS04.1: BAP1 Gene Mutation and Mesothelioma Pathogenesis - Michele Carbone, USA
  • 14:25 - MS04.2: Sequencing the Mesothelioma Genome - Where Wre We Now and Where Are We Going? - Raphael Bueno, USA
  • 14:45 - MS04.3: New Molecular Targets in Mesothelioma - Rolf Stahel, Switzerland
  • 15:05 - MS04.4: Current Clinical Trials of Targeted Therapies - Paul Baas, Netherlands

Mesothelioma
  14:00 - 15:30

E04: Lung Cancer Pathology Classification

Educational Session

Location: Parkside 110 A+B, Level 1

Chairs: Edwina Duhig, Australia & Ming Tsao, Canada

 

In 2011 a classification for adenocarcinoma was proposed by the IASLC, ATS and ERS. This classification had implications for the other major forms of carcinoma. Also, there has been further characterisation of the other forms with molecular genetics. This session is an update on current classification, the molecular features and where pathological characterisation will go in the future.

 

  • 14:00 - Chair Intro
  • 14:05 - E04.1: Adenocarcinoma - Masayuki Noguchi, Japan
  • 14:25 - E04.2: Squamous Cell Carcinoma - Andrew Nicholson, UK
  • 14:45 - E04.3: Large Cell and Sarcomatoid Carcinoma - Keith Kerr, UK
  • 15:05 - E04.4: Neuroendocrine Tumours - William Travis, USA

Pathology
  14:00 - 15:30

E05: Management of Pleural Effusion (Multiple Cases)

Educational Session

Location: Parkside Ballroom A, Level 1

Chairs: Y C Gary Lee, Australia & York Miller, USA

 

This will be a case-based discussion with a panel of experts. The intent is that each of the panel of experts will be primed to have a talk on one particular question in their own specialty area but this will be a moderated panel discussion with audience interaction. Key Learning Objectives are:

  • To define an investigational pathway for a likely malignant pleural effusion 
  • To understand the role of closed pleural fluid sampling, closed biopsies (if it exists) VATD and medical pleuroscopy in the investigation a malignant pleural effusion
  • To be aware of the optimal use of intercostals catheters and the range of options of closed sclerosant use (talc/povidone) 
  • To learn how to best deal with the problem of trapped lung

 

  • 14:00 - Chair Intro
  • 14:05 - E05.1: Introduction / Presentation of Case - Tajalli Saghaie, Australia
  • 14:10 - E05.2: First Presentation with Large Effusion - Diagnostic/ Treatment Pathway - Martin Phillips, Australia
  • 14:30 - E05.3: What Procedure - VATS/Medical Pleuroscopy in a Fit Patient - Pyng Lee, Singapore
  • 14:50 - E05.4: Small Tube vs Large Tube - Choice of Sclerosant - Ken Yoneda, USA
  • 15:10 - E05.5: Trapped Lung - What Do We Do - Paula Ugalde, Canada

Pulmonology
  14:00 - 15:30

MS01: Radiation as a Systemic Therapy

Mini Symposium

Location: Bayside 201 - 203, Level 2

Chairs: Bo Lu, USA & Paul van Houtte, Belgium

 

Radiotherapy is regarded as a “local” therapy, but there is increasing evidence that radiotherapy is associated with effects remote from the site of dose deposition. This session will address effects of radiotherapy on the immune response, its relationship to tumour cells in the peripheral circulation, the effects of tumour hypoxia on local tumour control and metastatic risk, and the use of functional imaging to identify and monitor local and metastatic disease in the radiotherapy patient.

 

  • 14:00 - Chair Intro
  • 14:05 - MS01.1: Immunomodulation With Radiotherapy - Quynh Le, USA
  • 14:25 - MS01.2: Circulating Tumour Cells as a Mechanism of Radio Resistance - Michael MacManus, Australia
  • 14:45 - MS01.3: Hypoxia as a Cause of Treatment Failure in NSCLC - Odd Terje Brustugun, Norway
  • 15:05 - MS01.4: Integration of Functional and Molecular Imaging in Radiotherapy Planning - Gerry Hanna, UK

Radiation Oncology
  14:00 - 15:30

E02: Radiation Toxicity

Educational Session

Location: Bayside Gallery A, Level 1

Chairs: Maria Werner-Wasik, USA & Francoise Mornex, France

 

Overview of acute and late toxicities of radiotherapy.  Mechanisms of injury.  Predisposing factors including genetic determinants. Clinical features and diagnosis. Prevention and treatment.

 

  • 14:00 - Chair Intro
  • 14:05 - E02.1: Cardiac Toxicity of Radiotherapy - Lawrence Marks, USA
  • 14:25 - E02.2: Radiation Oesophagitis - Jose Belderbos, Netherlands
  • 14:45 - E02.3: Functional Biophysical Model (FUNBIPM) to Predict Radiation Lung Toxicity - Feng-Ming Kong, USA
  • 15:05 - E02.4: Neurotoxicity of Cranial Irradiation - Alexander Sun, Canada

Radiation Oncology
  14:00 - 15:30

PC01: Clinical Trial Design for Drug Development

Pro-Con Session

Location: Parkside Ballroom B, Level 1

Chairs: Nise Yamaguchi, Brazil & Martin Stockler, Australia

 

Key Learning Objectives of this session are:

  • To understand the principles underpinning trial design for drug development in general
  • To understand traditional drug development trials methodology – pro/con
  • To understand the principle of adaptive clinical trial design for drug development – pro/con

 

  • 14:00 - PC01.1: Case Introduction - Mary Redman, USA
  • 14:10 - PC01.2: Adaptive Designs: For - J. Jack Lee, USA
  • 14:50 - PC01.3: Adaptive Designs: Against - Marc Buyse, Belgium

Statistics
  14:00 - 15:30

MS06: Surgeons as Drivers of NSCLC Research

Mini Symposium

Location: Bayside 105, Level 1

Chairs: Naveed Alam, Australia & Young Tae Kim, Korea

 

This session aims to educate surgeons on how to introduce research into their routine practice, and how surgeons themselves can become the drivers of research by creating and fostering a multidisciplinary research team.

 

  • 14:00 Chair Intro
  • 14:05 - MS06.1: How Do I Contribute to the IASLC Staging Projects? - Ramon Rami-Porta, Spain
  • 14:25 - MS06.2: Clinical Trial and Research Cooperation - Wen Zhao Zhong, China
  • 14:45 - MS06.3: Randomized Trial of VATS vs Axillary Thoracotomy for Lobectomy - Long Hao, China
  • 15:05 - MS06.4: Into the Lab: The Surgeon as Translational Researcher - Gavin Wright, Australia

Surgery
  14:00 - 15:30

MS05: Modern Management of Neuroendocrine Tumours

Mini Symposium

Location: Bayside Gallery B, Level 1

Chairs: Valerie Rusch, USA & Yi-Long Wu, China

 

This mini symposium will discuss the management of Neuroendocrine tumours across the spectrum of malignancy. Surgical extirpation, combined modality therapies, radionuclide therapies will be presented. Management of the rarer mediastinal neuroendocrine tumours will be described.

 

  • 14:00 - Chair Intro
  • 14:05 - MS05.1: Bronchopulmonary Carcinoids - Akira Iyoda, Japan
  • 14:25 - MS05.2: Combined Modality for LCNEC and Atypical Carcinoids - Eric Lim, UK
  • 14:45 - MS05.3: Mediastinal Neuroendocrine Tumours- Pier Luigi Filosso, Italy
  • 15:05 - MS05.4: Advances in Radionuclide Therapy - Dik Kwekkeboom, Netherlands

Surgery
     
  15:30 - 16:15

NETWORKING BREAK AND POSTER SESSION

Location: Exhibit Hall, Halls 4 + 5, Exhibition Centre, Ground Level

     
  15:40 - 16:10

EXHIBIT SHOWCASE SESSION

Location: Exhibit Showcase Theater, Exhibit Hall, Ground Level

Lilly Oncology: Maintenance Therapy: Experience, Patient Preferences, Discussion with Patient

 
       
  16:15 - 17:45

CONCURRENT ORAL AND MINI ORAL ABSTRACT SESSIONS

 

Click here for further abstract information.

 

Oral Abstract Sessions:

  • O08: Preclinical Therapeutic Models I
    Location: Bayside Auditorium A, Level 1
  • O09: General Thoracic Surgery
    Location: Parkside Ballroom B, Level 1
  • O10: Stereotactic Ablative Body Radiotherapy
    Location: Parkside 110 A+B, Level 1
  • O11: Symptom Management
    Location: Bayside Gallery A, Level 1

Mini Oral Abstract Sessions:

  • MO04: Lung Cancer Biology I
    Location: Bayside 103, Level 1
  • MO05: Prognostic and Predictive Biomarkers II
    Location: Parkside Auditorium, Level 1
  • MO06: NSCLC - Chemotherapy I
    Location: Parkside Ballroom A, Level 1
  • MO07: NSCLC - Targeted Therapies II
    Location: Bayside Auditorium B, Level 1
  • MO08: NSCLC - Early Stage
    Location: Bayside Gallery B, Level 1
  • MO09: Mesothelioma I
    Location: Bayside 204 A+B, Level 2
  • MO10: Molecular Pathology II
    Location: Bayside 104, Level 1
  • MO11: Screening and Epidemiology
    Location: Bayside 201 - 203, Level 2

 

     
   

SESSION WITH INVITED SPEAKERS

  16:15 - 17:45

G02: Global Lung Cancer Coalition (GLCC) Session: Deserve Better - Expect Better: Advocating for Better Outcomes for Lung Cancer Patients

General Session

Location: Bayside 105, Level 1

Chairs: Peter Goldstraw, UK & Matthew Peters, Australia

 

This session is hosted by the Global Lung Cancer Coalition – a coalition of 30 organisations from 21 countries. Attendees should gain a better understanding of current issues of importance in lung cancer advocacy. In particular, around public awareness of the disease and on the importance of audit, in improving outcomes for patients. Also, insights will be given into practical ways in which health professionals and patient advocates can make a difference. 

 

  • 16:15 - Chair Intro
  • 16:20 - G02.1: Public Awareness of Lung Cancer Symptoms - The GLCC/IPSOS MORI 2013 International Consumer Poll - Jessica Elgood, Australia
  • 16:36 - G02.2: Outcomes from Public Information Campaigns - Jesme Fox, UK
  • 16:52 - G02.3: Clinicians as Advocates: Raising Public Awareness of Lung Cancer - The West Japan Oncology Group Experience - Toshiyuki Sawa, Japan
  • 17:08 - G02.4: Survivors as Advocates: What is possible? - The Lung Cancer Alliance Experience - Kay Cofrancesco, USA
  • 17:24 - G02.5: How Clinicians and Patients Can Benefit From Better Data on Lung Cancer - Mick Peake, UK
  • 17:40 - G02.6: Closing Remarks, Including Comment on IASLC and Advocacy - The Future - Peter Goldstraw, UK
Supportive Care & Nurses
     
  18:00 - 19:30

INDUSTRY SUPPORTED SYMPOSIUM supported by Roche: Hitting the High Notes in NSCLC Therapy

Location: Parkside Auditorium, Level 1

     
     
  Tuesday, October 29
  07:00 - 08:00

CONCURRENT INDUSTRY SUPPORTED SYMPOSIA

 

  • Symposium supported by Novartis: Up Close and Personal: Future Targeted Strategies in NSCLC
    Location: Parkside Ballroom B, Level 1
  • Symposium supported by IASLC Radiotherapy Group (ART): What is the Appropriate Patient Population for SBRT?
    Simultaneous translation English >< Mandarin provided
    Location: Parkside Auditorium, Level 1

 

 
       
  07:00 - 08:00

CONCURRENT HIGHLIGHT OF THE DAYS SESSIONS

 

 
  07:00 - 08:00

HOD2: Monday's Highlights of the Day - Medical Oncology, Biology and Pathology

Highlight of the Day Session

Location: Bayside Auditorium B, Level 1

Chair: Robert Pirker, Austria

 

In this session speakers will summarize the best abstracts presented in medical oncology, biology and pathology on the previous day (Monday).

 

  • 07:00 - HOD2.1: Medical Oncology - Martin Edelman, USA
  • 07:20 - HOD2.2: Medical Oncology and Biology - Primo Lara, USA
  • 07:40 - HOD2.3: Pathology - Elisabeth Brambilla, France

Medical Oncology/ Biology/Pathology
  07:00 - 08:00

HOD1: Monday's Highlights of the Day - Radiotherapy, Radiology and Surgery

Highlight of the Day Session

Location: Bayside Auditorium A, Level 1

Chair: Jack Roth, USA

 

In this session speakers will summarize the best abstracts presented in radiotherapy, radiology and surgery on the previous day (Monday).

 

  • 07:00 - HOD1.1: Radiotherapy - Maria Werner-Wasik, USA
  • 07:30 - HOD1.2: Interventions, Radiology and Surgery - Masahiro Tsuboi, Japan
Radiotherapy/ Radiology/Surgery
       
  07:00 - 08:00

CONCURRENT MEET THE EXPERT SESSIONS

(ticketed sessions, incl. continental breakfast)

 

  07:00 - 08:00

MTE09: Cost Effectiveness of CT Screening

Meet the Expert Session (ticketed)

Location: Bayside 101, Level 1

Speaker: Christine Berg, USA

 

This educational session aims to develop and enhance knowledge resulting from modern LDCT screening for lung cancer including understanding how risk stratification may improve the efficiency of CT screening programs, the role of volumetrics for assessing nodules, the unique characteristics of screen detected nodules and cancers, as well as up-to-date IASLC recommendations.


Imaging/Screening
  07:00 - 08:00

MTE10: RECIST and PERCIST Criteria for Response to Therapy

Meet the Expert Session (ticketed)

Location: Bayside 102, Level 1

Speaker: David Shelton, USA

 

Understanding the strength and weaknesses of RECIST ad PERCIST criteria.


Imaging/Screening
  07:00 - 08:00

MTE11: How Do PDXs Help Us in the Clinic

Meet the Expert Session (ticketed)

Location: Bayside 103, Level 1

Speaker: Philip Mack, USA

 

Outline the current status of patient derived xenograft models & discuss potential clinical and translational applications.


Biology
  07:00 - 08:00

MTE12: The New Adenocarcinoma Classification Explained for Medical Oncologists

Meet the Expert Session (ticketed)

Location: Bayside 104, Level 1

Speaker: Gregory Riely, USA

 

This session is intended to provide a simplified and practical overview of the new adenocarcinoma classification specifically aimed at non-pathologists. Implications of the classification for patient management will also be discussed.


Medical Oncology
  07:00 - 08:00

MTE13: Airway Stenting - Rigid and Fibreoptic Techniques

Meet the Expert Session (ticketed)

Location: Bayside 105, Level 1

Speaker: Armin Ernst, USA

 

Airway stenting is a key palliative strategy alone or in combination with systemic treatment of central and endobronchial tumours. This is not a hands-on session so the emphasis will be on practicalities and the avoidance of catastrophic error. Examples of “I wish I had not done that” will be included.


Pulmonology
  07:00 - 08:00

MTE14: Second Line Chemotherapy in Mesothelioma - What is the Best Evidence?

Meet the Expert Session (ticketed)

Location: Bayside106, Level 1

Speaker: Giovanni Ceresoli, Italy

 

This session discusses the use of second line chemotherapy in mesothelioma, the evidence base for second line chemotherapy, and the practical role of second line chemotherapy in daily clinical practice.


Mesothelioma
  07:00 - 08:00

MTE15: Surgery for Complications of Surgery

Meet the Expert Session (ticketed)

Location: Bayside Gallery A, Level 1

Speaker: Young Tae Kim, Korea

 

This session will discuss the surgical re-intervention for common and unusual complications of surgery for NSCLC.


Surgery
  07:00 - 08:00

MTE16: Optimizing Thoracic Radiation Dose Schedule in Combined Modality Therapy in Stage III NSCLC

Meet the Expert Session (ticketed)

Location: Bayside Gallery B, Level 1

Speaker: Hak Choy, USA

 

This MTE session will discuss the central role of radiation therapy in obtaining local control of stage IIIA NSCLC and the best way to deliver radiation therapy.


Combined Modality
  07:00 - 08:00

MTE17: Nursing Goes Global - Meeting the Challenges Posed by Mesothelioma

Meet the Expert Session (ticketed)

Location: Bayside 201 - 203, Level 2

Chair: Beth Ivimey, Australia

Speakers: Mary Hesdorffer, USA & Liz Darlison, UK & Jocelyn McLean, Australia

 

Key Learning Objectives of this session are:

  • To highlight the global mesothelioma burden
  • To review the challenges posed by a mesothelioma diagnosis irrespective of patients location
  • Clarify the nursing priorities in meeting the needs of mesothelioma patients and their careers
  • Demonstrate the opportunities for nurses to unite globally to improve nursing care for mesothelioma patients and their careers.
  • 07:00 - Chair Intro
  • 07:05 - MTE17.1: The Driving Force of Social Networking - Mary Hesdorffer, USA
  • 07:20 - MTE17.2: Preparing to Meet the Growing Need - Liz Darlison, UK
  • 07:35 - MTE17.3: Surgical Options and Global Differences - Jocelyn McLean, Australia
  • 07:50 - MTE17.4: Discussion

Nursing/

Mesothelioma

  07:00 - 08:00

MTE21A: Genomics in Lung Cancer

Meet the Expert Session (ticketed)

Location: Bayside 204 A+B, Level 2

Speaker: Roman Thomas, Germany

 

Note: This is the same MTE Session as MTE21 scheduled on Wednesday, October 30. Due to high interest, the Wednesday Session is full, but Dr. Thomas agreed to repeat the session on Tuesday, October 29.

 

The aim of this MTE Session is to explore the question how do we apply genomics to the study and ultimately clinical use in lung cancer?


 
       
       
  08:15 - 09:45

PL03: Presidential Symposium Including Top Rated Abstracts

PLENARY SESSION

Location: Plenary Hall, Ground Level

   

Chairs: Michael Boyer, Australia & Kwun Fong, Australia

 

  • 08:15 - PL03.01: Lung Cancer Probability in Subjects with CT-Detected Pulmonary Nodules - Nanda Horeweg, Netherlands
  • 08:27 - PL03.02: Discussant - Christine Berg, USA
  • 08:37 - PL03.03: MesoVATS: A Multi-Centre Randomised Controlled Trial of Video Assisted Thoracoscopic Pleurectomy versus Talc Pleurodesis in Malignant Pleural Mesothelioma - Robert Rintoul, UK
  • 08:49 - PL03.04: Discussant - Valerie Rusch, USA
  • 08:59 - PL03.05: An Intergroup Randomized Phase III Comparison of Standard-Dose (60 Gy) versus High-Dose (74 Gy) Chemoradiotherapy (CRT) +/- Cetuximab (cetux) for Stage III Non-Small Cell Lung Cancer (NSCLC): Results on Cetux from RTOG 0617 - Gregory Masters, USA
  • 09:11 - PL03.06: Discussant - Jacek Jassem, Poland
  • 09:21 - PL03.07: Treatment with Therapies Matched to Oncogenic Drivers Improves Survival in Patients with Lung Cancers: Results from The Lung Cancer Mutation Consortium (LCMC) - Mark Kris, USA
  • 09:33 - PL03.08: Discussant - Ben Solomon, Australia
     
  09:45 - 10:30

NETWORKING BREAK AND POSTER SESSION

Location: Exhibit Hall, Halls 4 + 5, Exhibition Centre, Ground Level

       
  09:55 - 10:25

EXHIBIT SHOWCASE SESSION: BEST OF POSTERS - IASLC SELECTION - PART 1

Location: Exhibit Hall, Halls 4 + 5, Exhibition Centre, Ground Level

 
     
  10:30 - 12:00

CONCURRENT ORAL AND MINI ORAL ABSTRACT SESSIONS

 

Click here for further abstract information.

 

Oral Abstract Sessions:

  • O12: Lung Cancer Biology II
    Location: Parkside 110 A+B, Level 1
  • O13: Limited Resections
    Location: Bayside 204 A+B, Level 2
  • O14: Radiotherapy - Toxicity and Clinical Trials
    Location:
    Parkside Ballroom A, Level 1
  • O15: NSCLC - Chemotherapy II
    Location: Bayside Auditorium A, Level 1
  • O16: NSCLC - Targeted Therapies III
    Location: Parkside Auditorium, Level 1
  • O17: Anatomical Pathology I
    Location: Bayside 105, Level 1
  • O18: Cancer Control and Epidemiology II
    Location: Bayside 103, Level 1
  • O19: Support and Palliation I
    Location: Bayside 104, Level 1

Mini Oral Abstract Sessions:

  • MO12: Prognostic and Predictive Biomarkers III
    Location: Parkside Ballroom B, Level 1
  • MO13: SCLC I
    Location: Bayside 201 - 203, Level 2
  • MO14: Mesothelioma II - Surgery and Multimodality
    Location: Bayside Gallery B, Level 1

 

   

SESSION WITH INVITED SPEAKERS

 
  10:30 - 12:00

GR02: Is there a Role for the Thoracic Oncology Nurse in Ensuring Patients with an Advanced Lung Cancer Have Access to Early Phase Clinical Trials?

Grand Rounds Session

Location: Gallery A, Level 1

Chairs: Caitlin Broderick, Australia & Mary Hesdorffer, USA

 

This debate originated as there is concern in Thoracic Oncology that patients with an advanced lung cancer or Mesothelioma are denied access to early phase clinical trials.

 

  • 10:30 - Chair Intro
  • 10:35 - GR02.1: Affirmative - Patsy Yates, Australia
  • 10:50 - GR02.2: Affirmative - John White, UK
  • 11:05 - GR02.3: Negative - Melissa Culligan, USA
  • 11:20 - GR02.4: Negative - Yeur-Hur Lai, Taiwan
  • 11:35 - GR02.5: Discussion
Nursing
       
  12:15 - 13:45

INDUSTRY SUPPORTED SYMPOSIUM supported by Boehringer Ingelheim: Questions in the Treatment of NSCLC: Focus on EGFR Mutation-Positive NSCLC

Location: Bayside Auditorium B, Level 1

     
  14:00 - 15:30

CONCURRENT MINI SYMPOSIA AND EDUCATIONAL SESSIONS

 

  14:00 - 15:30

MS11: Next Generation Technology for Detection and Treatment of Lung Cancer

Mini Symposium

Location: Bayside Auditorium B, Level 1

Chair: Shinichi Toyooka, Japan & Tran Van Ngoc, Vietnam

 

High throughput sequencing at low cost is a demand driving innovation in molecular diagnosis.  “Next generation technology” is a term frequently used but what does it mean for the end user?  This session is meant to demystify the various methods under the next generation umbrella and how they are applicable to lung cancer diagnosis.  Also, how do we take these useful technologies and put them to use and where will they sit in the context of other techniques used in pathology laboratories.  Finally how do we incorporate these techniques into routine testing and reporting?

 

  • Next Generation Sequencing - Ramaswamy Govindan, USA
  • Validating Platforms for Routine Clinical Use - Paul Waring, Australia
  • The Role of Current Pathologic Techniques in the Next Gen World - Ignacio Wistuba, USA
  • Reporting and Interpreting Molecular Results - Ming Tsao, Canada

Pathology/Biology
  14:00 - 15:30

PC02: EGFR as a Target in Early Stage Disease

Pro-Con Session

Location: Parkside Auditorium, Level 1

Chairs: Nick Pavlakis, Australia & Jin Soo Lee, Korea

 

This session is designed to address the use of EGFR TKIs as adjuvant therapy in early stage, resected EGFR mutant positive NSCLC.

 

  • 14:00 - Chair Intro
  • 14:05 - PC02.1: Introduction: Detection of EGFR Mutations - Fred Hirsch, USA
  • 14:20 - PC02.2: Pro: Patients with EGFR Mutations Should Receive Adjuvant EGFR TKIs - Kazuhiko Nakagawa, Japan
  • 14:40 - PC02.3: Con: Patients with EGFR Mutations Should Not Receive Adjuvant EGFR TKIs - Chong Kin Liam, Malaysia
  • 15:00 - PC02.4: Adjudication and Discussion - Mark Kris, USA

Medical Oncology
  14:00 - 15:30

MS09: Immune Therapies for Lung Cancer

Mini Symposium

Location: Bayside Auditorium A, Level 1

Chairs: David Carbone, USA & Bruce Robinson, Australia

 

The aim of this session is to provide an overview of the role of the immune system in lung cancer with particular emphasis on the biology and rationale for activating T-cells via approaches targeting B7 family members (CTLA4, PD1, PD1L). Clinical trials targeting these mechanisms will also be discussed, along with vaccine approaches.

 

  • 14:00 - Chair Intro
  • 14:05 - MS09.1: Biology of the B7 Family Members (CTLA4, PD1, PDL1) - Scott Antonia, USA
  • 14:25 - MS09.2: Treatment Targeting PD1/PDL1 and Toxicity - Julie Brahmer, USA
  • 14:45 - MS09.3: Treatment Targeting CTLA4 Efficacy and Toxicity - Thomas Lynch, USA
  • 15:05 - MS09.4: Lung Cancer Vaccines - Johan Vansteenkiste, Belgium

Medical Oncology/Biology
  14:00 - 15:30

MS15: Extending the Limits of Combined Modality Treatment for NSCLC

Mini Symposium

Location: Bayside 201 - 203, Level 2

Chair: Mary O’Brien, UK & Ivan Tham, Singapore

 

This mini symposium will focus on recent advances and controversies in combined modality therapy for NSCLC.

 

  • 14:00 - Chair Intro
  • 14:04 - MS15.1: Targeted Therapy in Combined Modality Therapy for Intrathoracic NSCLC with Activating Mutations - Egbert Smit, Netherlands
  • 14:27 - MS15.2: Dose Escalation of Radiation in Combined Modality Therapy of NSCLC - Suresh Senan, Netherlands
  • 14:50 - MS15.3: Management of Patients with Oligometastatic/Resectable Stage IV NSCLC - Lun Xu Liu, China
  • 15:10 - MS15.4: Surgery After Induction Chemo/Radiation Therapy - Walter Weder, Switzerland

Combined Modality
  14:00 - 15:30

E09: Chemoprevention

Educational Session

Location: Bayside 104, Level 1

Chairs: Ugo Pastorino, Italy & Pan-Chyr Yang, Taiwan

 

This session will discuss the different preclinical models used to study the chemoprevention of Lung Cancer and review recent chemoprevention studies in humans and their methodological aspects. Finally, the opportunities provided by a new class of biomarkers –microRNAs – will be presented.

 

  • 14:00 - Chair Intro
  • 14:05 - E09.1: Preclinical Models for Lung Cancer Prevention - Luis Montuenga, Spain
  • 14:25 - E09.2: Clinical Chemoprevention Studies: Past, Present and Future - Robert Keith, USA
  • 14:45 - E09.3: Study Design and Response Assessment in Chemoprevention Trials - Eva Szabo, USA
  • 15:05 - E09.4: New Biomarkers for Chemoprevention Studies - Celine Mascaux, Canada

Prevention & Epidemiology
  14:00 - 15:30

E07: Staging in the Molecular Era

Educational Session

Location: Bayside 204 A+B, Level 2

Chair: Rayleen Bowman, Australia & Windfield Tan, Philippines

 

Staging has been markedly changed with the 7th IASLC TNM classification system, and this educational staging session will share learnings from image guided interventions, interaction with the new adenocarcinoma classification, and the new IASLC mesothelioma staging system.  In addition, we will learn the clinical utility of PET MRI to diagnose and stage lung cancer.

 

  • 14:00 - Chair Intro
  • 14:05 - E07.1: TNM Classification With Image Guided Interventions such as EBUS / EUS - Felix Herth, Germany
  • 14:25 - E07.2: Image Interpretation and New Adenocarcinoma-Classification - Kavita Garg, USA
  • 14:45 - E07.3: IASLC Staging Projects Update - Ramon Rami-Porta, Spain
  • 15:05 - E07.4: PET MRI for Diagnosis and Staging - Yasuko Ichikawa, Japan

Imaging/Screening
  14:00 - 15:30

MS12: Loco-Regional Management of MPM

Mini Symposium

Location: Bayside 103, Level 1

Chairs: Hans Hoffman, Germany & Takashi Nakano, Japan

 

To understand the current data and controversies in loco-regional management of MPM, with reference to clinical practice examples. The session includes surgical, radiation oncology, and intracavitary therapies.

 

  • 14:00 - Chair Intro
  • 14:04 - MS12.1: How Has the 'MARS' Trial Affected the Surgical Approach to MPM? - John Edwards, UK
  • 14:27 - MS12.2: Pleurectomy Decortication vs. Extrapleural Pneumonectomy - Jessica Donington, USA
  • 14:50 - MS12.3: Peri-Operative Radiotherapy: Current Data and State of the Art - Allan Price, UK
  • 15:10 - MS12.4: Adjuvant Intracavitary Treatments in Mesothelioma - Joseph Friedberg, USA

Mesothelioma
  14:00 - 15:30

MS10: Beyond Lung Cancer – The Pathology of Intra-Thoracic Mimics

Mini Symposium

Location: Bayside Gallery B, Level 1

Chair: Gang Chen, China & Yuichi Ishikawa, Japan

 

While primary carcinomas are the commonest tumours found on biopsy and resection, other tumours may present as lung lesions. This session is to cover some of the other and less common lesions that may occur in the lung and how they may be differentiated from primary lung carcinoma.

 

  • 14:00 - Chair Intro
  • 14:05 - MS10.1: Metastases to Lung and Differential Diagnosis - Ka Fai To, Hong Kong
  • 14:25 - MS10.2: Salivary Gland Tumours and Lymphoepithelioma-Like Carcinoma - Lucian Chirieac, USA
  • 14:45 - MS10.3: Pleural Neoplasms - Sonja Klebe, Australia
  • 15:05 - MS10.4: Pulmonary Sarcomas - Iver Petersen, Germany

Pathology
  14:00 - 15:30

E08: Early Endobronchial Tumours

Educational Session

Location: Bayside Gallery A, Level 1

Chairs: Noriaki Kurimoto, Japan & David Fielding, Australia

 

This session will present updates on the detection and definition of earlier stage central endobronchial malignancies particularly those that might be suitable for endobronchial interventions. There has been considerable technical advancement in treatment of malignancies in the upper respiratory tract in the past decade and there is a place for extending this progress to lung cancer. This occurs in the context that whilst central tumours are a lesser fraction in many countries this is not true globally.

 

  • 14:00 - Chair Intro
  • 14:05 - E08.1: Screening/Early Detection of Central Malignancy - Annette McWilliams, Canada
  • 14:25 - E08.2: Defining the Pathology - Dysplasia/Ca Insitu/Invasive Malignancy - Erik Thunnissen, Netherlands
  • 14:45 - E08.3: Endobronchial Interventions (PDT/Cryo/Surgery) - Daniela Gompelmann, Germany
  • 15:05 - E08.4: RT Approaches for Early Stage Central Tumours - Frank Lagerwaard, Netherlands

Pulmonology
  14:00 - 15:30

MS08: SABR

Mini Symposium

Location: Parkside Ballroom B, Level 1

Chair: Umberto Ricardi, Italy & Jose Belderbos, Netherlands

 

This session provides an update on controversial issues in the use of stereotactic ablative radiotherapy for thoracic cancers.

 

  • 14:00 - Chair Intro
  • 14:05 - MS08.1: Is SABR Safe for Central Disease? - Andrea Bezjak, Canada
  • 14:25 - MS08.2: Combining SABR and Targeted Agents - Ramesh Rengan, USA
  • 14:45 - MS08.3: SABR for Oligometastatic Disease - Billy Loo, USA
  • 15:05 - MS08.4: Dose Constraints in SABR - Masahiro Hiraoka, Japan

Radiation Oncology
  14:00 - 15:30

MS14: Interface Between Disease Modifying Treatment and Palliation

Mini Symposium

Location: Bayside 105, Level 1

Chair: Beth Ivimey, Australia & Lucy Morgan, Australia

 

The Learning Objective of this is session is to understand the intent of therapy for majority of patients with that stage of disease. 

 

  • 14:00 - Chair Intro
  • 14:05 - MS14.1: Sliding Slope Between Cure and Palliation: Local Cure in Disseminated Disease - Ben Slotman, Netherlands
  • 14:25 - MS14.2: Decision Making; When to Stop Disease Modifying Treatment - Christian Manegold, Germany
  • 14:45 - MS14.3: End of Life Discussions – Evidence-Based Communication - Josephine Clayton, Australia
  • 15:05 - MS14.4: Transition to End of Life Care - Chris Karapetis, Australia

Supportive Care
  14:00 - 15:30

GR01: Surgery and the New Stage IIIA

Grand Rounds Session

Location: Parkside Ballroom A, Level 1

Chairs: Frank Detterbeck, USA & John Mitchell, USA

 

Since the changes to the UICC/AJCC TNM staging system as proposed by the IASLC, there has been stage migration. Stage IIIA is now an even more heterogenous group. Strategies to approach the different entities within Stage IIIA are presented and new controversies unearthed.

 

  • 14:00 - Chair Intro
  • 14:05 - GR01.1: Surgery for N2 Disease: Where To and When To Now? - Masahiro Tsuboi, Japan
  • 14:25 - GR01.2: Where Does T3 End and T4 Begin? - Valerie Rusch, USA
  • 14:45 - GR01.3: Role of Neoadjuvant and Adjuvant Therapies - Shun-ichi Watanabe, Japan
  • 15:05 - GR01.4: Multiple Primaries, Satellites or Intrapulmonary Metastases? - Royce Calhoun, USA

Surgery
  14:00 - 15:30

MS13: Statistics of Personalised Medicine

Mini Symposium

Location: Parkside 110 A+B, Level 1

Chairs: Mary Redman, USA & John Crowley, USA

 

The Key Learning Objective of this session is to understand the evolution of clinical trials from empiric therapies to modern targeted therapies, how trial design has necessarily shifted from large scale inclusive trials to enriched studies incorporating molecula selection.

 

  • 14:00 - Chair Intro
  • 14:05 - MS13.1: A Review of Randomised Trials in Lung Cancer - Richard Stephens, UK
  • 14:25 - MS13.2: Clinical Trial Designs for Biomarker Driven Therapies in Advanced Disease - Roy Herbst, USA
  • 14:45 - MS13.3: Clinical Trial Designs for Biomarker Driven Therapies in Early Disease (Adjuvant) - Giorgio Scagliotti, Italy
  • 15:05 - MS13.4: The Future of RCTs in the Molecular Era? - David Gandara, USA

Statistics
     
  15:30 - 16:15

NETWORKING BREAK AND POSTER SESSION

Location: Exhibit Hall, Halls 4 + 5, Exhibition Centre, Ground Level

     
  16:15 - 17:45

CONCURRENT ORAL AND MINI ORAL ABSTRACT SESSIONS

 

Click here for further abstract information.

 

Oral Abstract Sessions:

  • O20: Staging and Advanced Disease
    Location: Parkside 110 A+B, Level 1
  • O21: SCLC II
    Location: Parkside Ballroom B, Level 1
  • O22: Mesothelioma III
    Location: Bayside Gallery A, Level 1
  • O23: Imaging and Screening
    Location: Bayside 201 - 203, Level 2
  • O24: Cancer Control & Epidemiology III
    Location: Bayside 103, Level 1
  • O25: Stigma and Nihilism
    Location: Bayside Gallery B, Level 1
  • O26: Support and Palliation II
    Location: Bayside 104, Level 1
  • O27: Clinical Trials and Practice
    Location: Bayside Auditorium A, Level 1

Mini Oral Abstract Sessions:

  • MO15: Novel Genes and Pathways
    Location: Parkside Ballroom A, Level 1
  • MO16: Prognostic and Predictive Biomarkers IV
    Location: Parkside Auditorium, Level 1
  • MO17: Radiotherapy I: Stereotactic Ablative Body Radiotherapy
    Location: Bayside 204 A+B, Level 2
  • MO18: NSCLC - Targeted Therapies IV
    Location: Bayside Auditorium B, Level 1
     
  18:00 - 19:30

INDUSTRY SUPPORTED SYMPOSIUM supported by Roche: New Horizons in First-Line NSCLC Therapy

Location: Parkside Auditorium, Level 1

     
     
  Wednesday, October 30
  07:00 - 08:00

INDUSTRY SUPPORTED SYMPOSIUM supported by IASLC Radiotherapy Group (ART): What is the Appropriate Patient Population for IGRT?

Simultaneous translation English >< Mandarin provided

Location: Parkside Auditorium, Level 1

 
       
  07:00 - 08:00

CONCURRENT HIGHLIGHT OF THE DAY SESSIONS

 

 
  07:00 - 08:00

HOD4: Tuesday's Highlights of the Day - Medical Oncology, Biology, Radiotherapy and Combined Modality

Highlight of the Day Session

Location: Bayside Auditorium B, Level 1

Chair: John Heymach, USA

 

In this session speakers will summarize the best abstracts presented in medical oncology, biology and radiotherapy on the previous day.

 

  • 07:00 - HOD4.1: Medical Oncology and Biology - Suresh Ramalingam, USA
  • 07:30 - HOD4.2:Radiotherapy and Combined Modality - Andrea Bezjak, Canada

Medical Oncology/ Biology/Radiotherapy/ Combined Modality
  07:00 - 08:00

HOD3: Tuesday's Highlights of the Day - Surgery, Staging, Imaging and Pulmonary

Highlight of the Day Session

Location: Bayside Auditorium A, Level 1

Chair: Walter Weder, Switzerland

 

In this session speakers will summarize the best abstracts presented in surgery, staging, imaging and pulmonary on the previous day(s).

 

  • 07:00 - HOD3.1: Surgery and Staging - Hiroshi Date, Japan
  • 07:30 - HOD3.2: Imaging and Pulmonary (2 Day Coverage) - Pieter Postmus, Netherlands
Surgery/Staging/ Imaging/Pulmonary
       
       
  07:00 - 08:00

CONCURRENT MEET THE EXPERT SESSIONS

(ticketed sessions, incl. continental breakfast)

 

  07:00 - 08:00

MTE18: PET-CT for Staging, Judging Response to Therapy, Restaging

Meet the Expert Session (ticketed)

Location: Bayside 101, Level 1

Speaker: Jeremy Erasmus, USA

 

The aim of this MTE session is to explore how to use CT-PET for staging, response prediction and restaging.


Imaging/Staging
  07:00 - 08:00

MTE19: Biology and Treatment of Thymoma/Thymic Carcinoma

Meet the Expert Session (ticketed)

Location: Bayside 102, Level 1

Speaker: Nicolas Girard, France

 

This session aims to provide an overview of the biologic features of thymoma and thymic carcinoma, as well as an outline of the chemotherapeutic management of these tumours.


Medical Oncology/Surgery
  07:00 - 08:00

MTE20: Pathology of Mesothelioma

Meet the Expert Session (ticketed)

Location: Bayside 103, Level 1

Speaker: Victor Roggli, USA

 

Pathological diagnosis of malignant mesothelioma remains problematic. Now we are asked to make diagnosis on ever smaller quantities of tissue. However it remains a fine line between reactive and malignant and between mesothelial and non-mesothelial tumours. Is there in situ and when is it invasive? The speaker is asked: how do we negotiate these shades of grey?


Mesothelioma/Pathology
  07:00 - 08:00

MTE21: Genomics in Lung Cancer

Meet the Expert Session (ticketed)

Location: Bayside 104, Level 1

Speaker: Roman Thomas, Germany

 

FULL - The session will be repeated on Tuesday, October 29 from 07:00 - 08:00.

 

The aim of this MTE Session is to explore the question how do we apply genomics to the study and ultimately clinical use in lung cancer?


Pathology
  07:00 - 08:00

MTE22: A Practical Approach to the Incidental Pulmonary Nodule

Meet the Expert Session (ticketed)

Location: Bayside 105, Level 1

Speakers: David Midthun, USA & David Milne, New Zealand

 

There are now many small nodules detected either incidentally or as part of lung cancer screening programs. Drawing on the experience the Key Learning Objectives of this MTE Session are:

  • To learn the different nodule characteristics
  • To understand the relationship between nodule characteristics and preferred management pathways
  • To understand the relationship between nodule characteristics and preferred management pathways To be aware of the potential hazards of radiation and its impact on optimal monitoring
  • To be able to create a QA plan for monitoring personal management of SPNs
  • 07:00 - MTE22.1: A Practical Approach to the Incidental Pulmonary Nodule - David Midthun, USA
  • 07:30 - MTE22.2: A Practical Approach to the Incidental Pulmonary Nodule - David Milne, New Zealand

Pulmonology
  07:00 - 08:00

MTE23: Screening Tools for a High Risk Population - Can We Screen for Early Mesothelioma?

Meet the Expert Session (ticketed)

Location: Bayside 106, Level 1

Speaker: Jan van Meerbeeck, Belgium

 

This session provides an overview of the current status of screening for early mesothelioma, including the range of potential screening methodologies, current status, current trials, and the clinical significance of detecting early clinical stage mesothelioma.


Mesothelioma
  07:00 - 08:00

MTE24: Treatment of Cachexia Over the Next Five Years

Meet the Expert Session (ticketed)

Location: Bayside Gallery A, Level 1

Speaker: Peter Martin, Australia

 

Participants in this session will have new insights into the pathphysiology of cachexia and potential targeted therapeutic pathways as a result. An understanding of the current clinical trial progress in changing the clinical course of cachexia beyond anti-cancer therapies.


Supportive Care
  07:00 - 08:00

MTE25: Less than Pneumonectomy after XRT (High Dose Radiotherapy)

Meet the Expert Session (ticketed)

Location: Bayside Gallery B, Level 1

Speaker: Kenji Suzuki, Japan

 

This session will present the surgical techniques and results of surgery after high dose radiation to the lung and mediastinum, including parenchymal salvage and reinforcement with autologous grafts.

Surgery
     
  08:15 - 09:45

PL04: How Can We Stop the Epidemic of Lung Cancer?

PLENARY SESSION

Location: Plenary Hall, Ground Level

Epidemiology
   

Chairs: Chris Amos, USA & Caicun Zhou, China

 

This session will bring the most recent data on the positive effects of smoking cessation, the risk factors for Lung Cancer in non-smokers, the effect of Lung Cancer screening by low-dose CT and the place of biomarkers in Lung Cancer screening.

 

  • 08:15 - Chair Intro
  • 08:20 - PL04.1: Risk Reduction by Stopping Smoking - Valerie Beral, UK
  • 08:40 - PL04.2: Risk Factors for Lung Cancer in Never-Smokers - Chien-Jen Chen, Taiwan
  • 09:00 - PL04.3: A Critical Review of CT Lung Cancer Screening - Elisabeth Quoix, France
  • 09:20 - PL04.4: Biomarker-Driven Programs for Lung Cancer Screening - Pierre Massion, USA
     
  09:45 - 10:30

NETWORKING BREAK AND POSTER SESSION

Location: Exhibit Hall, Halls 4 + 5, Exhibition Centre, Ground Level

       
  09:55 - 10:25

EXHIBIT SHOWCASE SESSION: BEST OF POSTERS - IASLC SELECTION - PART 2

Location: Exhibit Hall, Halls 4 + 5, Exhibition Centre, Ground Level

 
     
  10:30 - 12:00

CONCURRENT ORAL AND MINI ORAL ABSTRACT SESSIONS

 

Click here for further abstract information.

 

Oral Abstract Sessions:

  • O28: Endoscopy
    Location: Parkside Auditorium, Level 1
  • O29: Cancer Control & Epidemiology IV
    Location: Bayside 103, Level 1

Mini Oral Abstract Sessions:

  • MO19: Lung Cancer Immunobiology
    Location: Bayside 201 - 203, Level 2
  • MO20: Preclinical Therapeutic Models II
    Location: Bayside Gallery B, Level 1
  • MO21: Prognostic and Predictive Biomarkers V - EGFR
    Location: Bayside Auditorium A, Level 1
  • MO22: Advanced Disease and Outcomes
    Location: Parkside 110 A+B, Level 1
  • MO23: Radiotherapy II: Lung toxicity, Target Definition and Quality Assurance
    Location: Bayside 204 A+B, Level 2
  • MO24: NSCLC - Chemotherapy III
    Location: Parkside Ballroom A, Level 1
  • MO25: NSCLC - Combined Modality Thearpy II
    Location: Parkside Ballroom B, Level 1
  • MO26: Anatomical Pathology II
    Location: Bayside 105, Level 1
  • MO27: Patient Centred Care
    Location: Bayside 104, Level 1
     
  10:30 - 12:00

SESSIONS WITH INVITED SPEAKERS

  10:30 - 12:00

MS16: ESTS/IASLC Thymic Session

Mini Symposium

Location: Bayside Gallery A, Level 1

Chairs: Peter Goldstraw, UK & Eric Lim, UK

 

  • 10:30 - MS16.1: Pathological Classification of Thymic Tumours in the Molecular Age: Proposals for the Next WHO Classification - William Travis, USA
  • 10:47 - MS16.2: Towards a TNM-Based Prognostic Classification for Thymic Tumours - Frank Detterbeck, USA
  • 11:04 - MS16.3: Surgery for Thymic Tumours: Outcomes from the ESTS Data Base - Enrico Ruffini, Italy
  • 11:21 - MS16.4: Chemotherapy for Thymic Tumours - Nicolas Girard, France
  • 11:38 - MS16.5: Radiotherapy for Thymic Tumours: Induction, Adjuvant and Definitive - Ritsuko Komaki, USA

Thymic
  10:30 - 12:00

MS27: Mechanisms of Acquired Resistance to Targeted Therapy

Mini Symposium

Location: Bayside Auditorium B, Level 1

Chairs: Seiji Yano, Japan & Ben Solomon, Australia

 

Despite dramatic initial responses observed in NSCLC patients treated with targeted therapies tumours invariably develop resistance leading to treatment failure. The mechanisms leading to “acquired resistance” to EGFR inhibitors and ALK inhibitors will be described together with clinical strategies to overcome acquired resistance.

 

  • 10:30 - Chair Intro
  • 10:35 - MS27.1: Resistance to EGFR TKIs - Seiji Yano, Japan
  • 10:55 - MS27.2: Resistance to ALK Inhibitors - Robert Doebele, USA
  • 11:15 - MS27.3: Clinical definition of TKI Resistance and How to Overcome It - Pasi Janne, USA
  • 11:35 - MS27.4: Trial Design as it Applies to Resistance - Jean-Charles Soria, France
Medical Oncology/Biology
     
  12:15 - 13:45

INDUSTRY SUPPORTED SYMPOSIUM supported by BMS: Perspectives in Lung Cancer: Is Immuno-Oncology the New Treatment Paradigm?

Location: Plenary Hall, Level 1

     
  14:00 - 15:30

CONCURRENT MINI SYMPOSIA AND EDUCATIONAL SESSIONS

 

  14:00 - 15:30

E11: Practical Aspects of Targeted Therapies

Educational Session

Location: Plenary Hall, Ground Level

Chairs: Michael Millward, Australia & Luis Paz-Ares, Spain

 

This education session is intended to provide practising clinicians with information that is relevant to their daily practice relating to the use of targeted therapies.

 

  • 14:00 - Chair Intro
  • 14:05 - E11.1: Who Should We Test for Genetic Alterations, When and How? - Rolf Stahel, Switzerland
  • 14:25 - E11.2: Management Options at First Progression of EGFR Mutant Tumors - Keunchil Park, Korea
  • 14:45 - E11.3: Panel Discussion: MDT - Managing Toxicities and Evaluating Drug Interactions - Pan-Chyr Yang, Taiwan & Kenneth O'Byrne, Ireland & Anne Fraser, New Zealand

Medical Oncology
  14:00 - 15:30

MS20: Small Cell Lung Cancer

Mini Symposium

Location: Bayside 204 A+B, Level 2

Chairs: Nevin Murray, Canada & Egbert Smit, Netherlands

 

This is a session devoted entirely to small cell lung cancer.

 

  • 14:00 - Chair Intro
  • 14:05 - MS20.1: The Clinical Challenge of Small Cell Lung Cancer - Chandra Belani, USA
  • 14:25 - MS20.2: Small Cell Cancer Biology: Recent Insights - David Carbone, USA
  • 14:45 - MS20.3: Optimal Radiotherapy for SCLC - Corinne Faivre-Finn, UK
  • 15:05 - MS20.4: New Treatments for SCLC - Alex Adjei, USA

Medical Oncology
  14:00 - 15:30

E10: Targeting KRAS in Lung Cancer

Educational Session

Location: Parkside Auditorium, Level 1

Chairs: Christine Lovly, USA & Erik Thunnissen, Netherlands

 

KRAS mutations occur in 20-30% of all lung adenocarcinomas and have until recently been considered to be "undruggable". The biology and clinical associations together with the predictive and prognostic significance of KRAS mutations in NSCLC will be discussed. Novel strategies to target KRAS mutations in preclinical models and in clinical trials will be discussed.

 

  • 14:00 - Chair Intro
  • 14:05 - E10.1: Biology - Tetsuya Mitsudomi, Japan
  • 14:30 - E10.2: Predictive or Prognostic Role of KRAS - Frances Shepherd, Canada
  • 14:55 - E10.3: Targeting KRAS and KRAS Signaling in the Clinic - Gregory Riely, USA

Biology
  14:00 - 15:30

MS17: Imaging Developments

Mini Symposium

Location: Bayside Auditorium A, Level 1

Chairs: James Jett, USA & Elisna Syahruddin, Indonesia

 

This Mini Symposium will present current and future trends in imaging for lung cancer. It will review the promise of molecular imaging and therapeutic radionuclides, how to harmonise and standardise imaging protocols and reporting, identify the correlation of various imaging modalities with pathology and clinical response.

 

  • 14:00 - Chair Intro
  • 14:05 - MS17.1: Molecular Imaging - Where Are We and Where Is It Going - Tim Akhurst, Australia
  • 14:25 - MS17.2: Standardized Reporting; Guidelines for Imaging Protocols / Interpretation - Anand Devaraj, UK
  • 14:45 - MS17.3: Correlation of PET, CT and MRI with Pathology and Response - Denise Aberle, USA
  • 15:05 - MS17.4: Radiotracers in Imaging and Therapy of Thoracic Oncology - Tim Akhurst, Australia

Imaging/Screening
  14:00 - 15:30

MS24: Mesothelioma Biology and Biomarkers

Mini Symposium

Location: Bayside 104, Level 1

Chairs: Bruce Robinson, Australia & Harvey Pass, USA

 

The Key Learning Objective of this session is to understand the current laboratory models and techniques being used for discovery projects in mesothelioma, together with cutting edge results from leaders in the field.

 

  • 14:00 - Chair Intro
  • 14:04 - MS24.1: A Tractable Animal Model of Mesothelioma - Richard Lake, Australia
  • 14:24 - MS24.2: In Vitro Models in Mesothelioma - Courtney Broaddus, USA
  • 14:47 - MS24.3: Apoptosis and Chemoresistance - Sara Busacca, UK
  • 15:07 - MS24.4: New Biomarker Research in Mesothelioma - Jenette Creaney, Australia

Mesothelioma
  14:00 - 15:30

MS26: Exploring the Diverse Impact that the Thoracic Oncology Nurse Can Make…

Mini Symposium

Location: Bayside 105, Level 1

Chair: Mary Duffy, Australia & Diana Borthwick, UK

 

Specialist lung cancer nurses have contact with lung cancer patients at many time points throughout patient illness trajectory. The aim of this session is to explore the variety of clinical nursing interventions specialists’ nurses can contribute.

 

  • 14:00 - Chair Intro
  • 14:05 - MS26.1: Symptom Clusters - Alex Molassiotis, Hong Kong
  • 14:25 - MS26.2: Exploration of the Nurse Role in Follow Up Care - Liz Darlison, UK
  • 14:45 - MS26.3: Exercise and Lung Cancer Survivorship - Stacie Corcoran, USA
  • 15:05 MS26.4: Stigma & Nihilism - International Nursing Perspective - Maria Eliana San Martin, Chile

Nursing
  14:00 - 15:30

MS22: The Mediastinum 2013

Mini Symposium

Location: Parkside 110 A+B, Level 1

Chairs: Felix Herth, Germany & Chunxue Bai, China

 

Nothing causes as much angst as mediastinal staging. There is so much talk of the mediastinum that a basic of anatomy and imaging will be useful followed by presentations on use of anatomical knowledge plus procedural skills to ‘fully’ stage in the pre-definitive treatment setting. The Key Learning Objectives of this session are:

  • To understand normal mediastinal anatomy
  • To understand the merits of imaging techniques/modalities. Is there a niche for MRI?
  • To learn the advances in EBUS/EUS. Diagnostic yield and limitations.
  • To be aware of the residual role of surgical exploration – incremental benefits and any incremental risks.

 

  • 14:00 - Chair Intro
  • 14:05 - MS22.1: The Anatomy of the Mediastinum/CT Imaging - Noriaki Kurimoto, Japan
  • 14:25 - MS22.2: Further Staging Using Imaging - PET, MRI and PET/CT - Edward Hsiao, Australia
  • 14:45 - MS22.3: Minimally Invasive and Endoscopic Options - Daniela Gompelmann, Germany
  • 15:05 - MS22.4: Surgical Techniques for Definitive Staging - Ugo Pastorino, Italy

Pulmonology
  14:00 - 15:30

MS23: Treatment of the Small Malignant Nodule

Mini Symposium

Location: Bayside Auditorium B, Level 1

Chair: Tom Sutedja, Netherlands & Soon Hin How, Malaysia

 

This will be based on a single case. A patient with a 5 year history of CRC who is found to have a single malignant nodule. FNABx shows adenocarcinoma – could be lung could be solitary metastasis.  PET single lesion. Ex-smoker with impaired lung function – something to put him at increased risk of lobectomy. The Key Learning Objectives of this session are:

  • To understand the arguments for and against biopsy confirmation before treatment
  • To understand the range of possible interventions for a small malignant nodule 
  • To understand the particular merits of each – procedural risks etc
  • To be aware of recent improvements/innovations/data for this range of interventions

 

  • 14:00 - Chair Intro
  • 14:05 - MS23.1: Introduction / Presentation of Case - Helen Jo, Australia
  • 14:10 - MS23.2: Is Tissue Diagnosis Necessary? - Daniel Steinfort, Australia
  • 14:27 - MS23.3: SABR for Early Stage Lung Cancer and Pulmonary Oligometastases - Hiroshi Onishi, Japan
  • 14:44 - MS23.4: Surgery for Early Stage Lung Cancer and Oligometastases - Hisao Asamura, Japan
  • 15:01 - MS23.5: Thermal Ablation for Early Stage Lung Cancer and Oligometastases - Karin Steinke, Australia
  • 15:18 - MS23.6: Panel Discussion

Pulmonology/Radiation Onc.
  14:00 - 15:30

MS21: Practical Problems in Lung Cancer Diagnosis – Application of the 2011 Adenocarcinoma Classification

Mini Symposium

Location: Bayside Gallery A, Level 1

Chairs: Andre Moreira, USA & Prudence Russell, Australia

 

The 2011 classification of adenocarcinoma, as proposed by the IASLC, American Thoracic Society and European Respiratory Society changed the approach of pathologists.  Not only did it change how adenocarcinoma was reported but it had on impact how all specimens were reported, particularly small biopsies and cytological specimens.   This session covers the various specimen types and the various techniques used in a pathology laboratory and how each is used or applied under the auspices of this classification.  It also examines potential difficulties with that may arise during reporting.

 

  • 14:00 - Chair Intro
  • 14:05 - MS21.1: Cytological Diagnosis - Kim Geisinger, USA
  • 14:22 - MS21.2: Molecular Diagnosis in Cytology and Its Place in the New Classification - Sandra O'Toole, Australia
  • 14:39 - MS21.3: Immunohistochemistry and the New Classification - Guiseppe Pelosi, Italy
  • 14:56 - MS21.4: AIS and the Well Differentiated Spectrum - Yasushi Yatabe, Japan
  • 15:13 - MS21.5: Molecular Analysis for Distinction Second Primary of the Lung vs Lung Metastasis? - Sanja Dacic, USA

Pathology
  14:00 - 15:30

MS18: Optimizing Control of Local and Medastatic NSCLC with Radiotherapy

Mini Symposium

Location: Bayside 201 - 203, Level 2

Chairs: Ritsuko Komaki, USA & Kazushige Hayakawa, Japan

 

This session explores novel radiotherapy strategies for improving outcomes in non-small cell lung cancer.

 

  • 14:00 - Chair Intro
  • 14:05 - MS18.1: Why Did 74Gy Fail - Walter Curran Jr., USA
  • 14:25 - MS18.2: Altered Fractionation - Cecile Le Pechoux, France
  • 14:45 - MS18.3: Re-Irradiation Following Radical Radiotherapy - Dirk De Ruysscher, Netherlands
  • 15:05 - MS18.4: Radiation and Re-Irradiation of CNS Metastasis - Luhua Wang, China

Radiation Oncology
  14:00 - 15:30

E12: Symptom Control - Pain, Dyspnoea and Fatigue

Educational Session

Location: Bayside 103, Level 1

Chairs: Patricia Davidson, Australia & David Currow, Australia

 

The Key Learning Objective of this session is to understand the evidence-based approaches to reducing chronic refractory dyspnoea in people with lung cancer.

 

  • 14:00 - Chair Intro
  • 14:05 - E12.1: Dyspnoea - David Currow, Australia
  • 14:30 - E12.2: Pain - Miriam Johnson, UK
  • 14:55 - E12.3: Fatigue and Exercise - Sharon Kilbreath, Australia

Supportive Care
  14:00 - 15:30

E13: High Risk Patients and Low Risk Surgeons

Educational Session

Location: Parkside Ballroom A, Level 1

Chairs: Hiroshi Date, Japan & Royce Calhoun, USA

 

This session is aimed at improving the standards of surgery by better decision-making, audit and benchmarking. The practical aspects of high risk surgery after radiation will be presented.

 

  • 14:00 - Chair Intro
  • 14:05 - E13.1: Salvage Surgery After Radiation: Residual Tumour and Complications - Marinus Paul, Netherlands
  • 14:25 - E13.2: Standards and Benchmarking of Surgery - Alex Brunelli, Italy
  • 14:45 - E13.3: Micrometastases: Magic or Mainstream? - Yi-Long Wu, China
  • 15:05 - E13.4: Decision-Making and the New IASLC Staging System - Peter Goldstraw, UK

Surgery
  14:00 - 15:30

MS25: Translating Research Into Practice (Applied Statistics)

Mini Symposium

Location: Bayside Gallery B, Level 1

Chair: Mary O’Brien, UK & Richard Stephens, UK

 

The Key Learning Objectives of this session are:

  • To appreciate the evolution of OS as the original gold standard for determining clinical benefit.
  • To appreciate the evolution of evidence supporting lines of therapy in lung cancer and how that affects interpretation of PFS and OS in clinical trial design.
  • To appreciate PFS as a valid statistical endpoint and its relationship to OS.
  • To understanding the principles underpinning a successful screening test and the nuances involved in screening trial design.
  • To understand and appreciate the principles behind cost effectiveness of modern therapies, how this is used to rationalize drug choice and drug reimbursement.

 

  • 14:00 - Chair Intro
  • 14:05 - MS25.1: Defining the Gold Standard: PFS v OS - Katsuyuki Hotta, Japan
  • 14:25 - MS25.2: Statistical Requirements for Screening Trials - Lucinda Billingham, UK
  • 14:45 - MS25.3: Cost-Effectiveness of Modern Therapies - Natasha Leighl, Canada
  • 15:05 - MS25.4: Assessing New Treatments for Lung Cancer - Regulatory and Cost-Effectiveness Implications - Suzanne Hill, Australia

Statistics
  14:00 - 15:30

MS19: New Health Technology for Lung Cancer; Assessment and Implementation

Mini Symposium

Location: Parkside Ballroom B, Level 1

Chairs: Yolande Lievens, Belgium & Feng-Ming (Spring) Kong, USA

 

  • 14:00 - Chair Intro
  • 14:05 - MS19.1: Assessing New Technology in Lung Cancer Radiotherapy - Fergus Macbeth, UK
  • 14:25 - MS19.2: Cost Effectiveness of Prevention of Lung Cancer (Developed and Developing World) - Carolyn Dresler, USA
  • 14:45 - MS19.3: Resource Constraints as a Barrier to Lung Cancer Management: Developing Nations - Sumitra Thongprasert, Thailand
  • 15:05 - MS19.4: Resource Constraints as a Barrier to Lung Cancer Management: Developed Nations - William Evans, Canada
All tracks
     
  15:30 - 16:15

NETWORKING BREAK AND POSTER SESSION

Location: Exhibit Hall, Halls 4 + 5, Exhibition Centre, Ground Level

     
  16:15 - 17:45

PL05: Genomics: From Research Tool to the Lung Cancer Clinic

CLOSING PLENARY SESSION

Location: Plenary Hall, Ground Level

Chairs: Peter Goldstraw, UK & Tony Mok, Hong Kong

 

  • 16:15 - Chair Intro
  • 16:20 - PL05.1: Implications of the Lung Cancer Genome Sequencing - Ramaswamy Govindan, USA

    This talk will place genomic discoveries from the TCGA, ICGC and other international efforts into our conventional clinico-pathological framework of tumour biology, behaviour, prognosis, drug sensitivity and resistance. It will highlight the potential benefits envisaged from exploiting massively parallel sequencing for the patient and the clinician in the near term, and discuss the system issues and health reforms required to make this paradigm a reality.

 

  • 16:45 - PL05.2: Challenges in Bioinformatics - Yu Shyr, USA

    Participants will learn about the current bioinformatic techniques employed to interrogate the vast amounts of data from genomic studies of a single cancer, validation and QC to identify relevant putative driver and passenger mutations from which therapeutic decisions can be reliably based. Given the mountain of data from massively parallel sequencing, the talk will also describe current and future efforts to deliver the right genomic information to the clinician and patient at the right time to ensure the right treatment rather than being swamped by unactionable molecular aberrations.

  • 17:10 - PL05.3: Challenges for the Clinician - Chandra Belani, USA

    Personalised precision medicine is a popular concept that is driving research and practice, and enabled by the incredibly rapid technological advances in genomic medicine and platforms. However, from time to time, medical practice has seen promising advances fail to make it to the clinic for a variety of reasons. The talk will discuss the structural framework challenges that will need to be addressed for successful genomic translation into the clinic to realise benefits for patients. These obstacles include system requirements (ethical, governance, financial, regulatory, quality and safety, implementation to the health system, etc), clinician factors (reluctance to change, re-learning genetics and genomics, workload, relevance, communication, etc) and most importantly patient factors (comprehensibility, acceptability, privacy, costs, consequences, etc).

     

  • 17:35 - PL05.4: Closing remarks and Invitation to Denver, 2015 - Michael Boyer, Australia & Kwun Fong, Australia & Fred Hirsch, USA
 
       

 

 

Program by Tracks

 

Sessions by Track

 

BIOLOGY

MEDICAL ONCOLOGY

COMBINED MODALITY

EPIDEMIOLOGY

IMAGING/STAGING

MESOTHELIOMA

NURSING

PATHOLOGY

PULMONOLOGY

RADIATION ONCOLOGY

STATISTICS

SUPPORTIVE CARE

SURGERY

THYMIC TUMOURS